Ckd Bio Asset Resilience Ratio
Ckd Bio asset resilience ratio. Ckd Bio (063160) has an Asset Resilience Ratio of 0.02% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Ckd Bio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Ckd Bio (2011–2025)
Asset resilience ratio of Ckd Bio from 2011 to 2025. This chart shows how Ckd Bio's Asset Resilience Ratio has changed over time. Read Ckd Bio total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Ckd Bio's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Ckd Bio (063160) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩70.33 Million | 0.02% |
| Total Liquid Assets | ₩70.33 Million | 0.02% |
Asset Resilience Insights
- Limited Liquidity: Ckd Bio maintains only 0.02% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Ckd Bio Industry Peers by Asset Resilience Ratio
Compare Ckd Bio's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Ckd Bio Asset Resilience Ratio by Year (2011–2025)
Ckd Bio asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for Ckd Bio.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.02% | ₩70.20 Million ≈ $47.57K |
₩299.87 Billion ≈ $203.22 Million |
0.00pp |
| 2024-12-31 | 0.02% | ₩69.92 Million ≈ $47.38K |
₩284.49 Billion ≈ $192.80 Million |
+0.00pp |
| 2023-12-31 | 0.02% | ₩69.55 Million ≈ $47.13K |
₩293.79 Billion ≈ $199.09 Million |
-2.56pp |
| 2022-12-31 | 2.58% | ₩8.07 Billion ≈ $5.47 Million |
₩312.59 Billion ≈ $211.84 Million |
+2.56pp |
| 2021-12-31 | 0.02% | ₩69.03 Million ≈ $46.78K |
₩298.54 Billion ≈ $202.32 Million |
0.00pp |
| 2020-12-31 | 0.02% | ₩69.99 Million ≈ $47.43K |
₩283.46 Billion ≈ $192.10 Million |
-0.01pp |
| 2019-12-31 | 0.03% | ₩71.58 Million ≈ $48.51K |
₩233.35 Billion ≈ $158.14 Million |
-2.60pp |
| 2018-12-31 | 2.63% | ₩4.86 Billion ≈ $3.29 Million |
₩184.52 Billion ≈ $125.05 Million |
-0.70pp |
| 2017-12-31 | 3.34% | ₩5.99 Billion ≈ $4.06 Million |
₩179.48 Billion ≈ $121.63 Million |
+2.26pp |
| 2016-12-31 | 1.07% | ₩1.94 Billion ≈ $1.32 Million |
₩180.91 Billion ≈ $122.60 Million |
+0.86pp |
| 2014-12-31 | 0.22% | ₩360.00 Million ≈ $243.97K |
₩165.07 Billion ≈ $111.86 Million |
-0.94pp |
| 2011-12-31 | 1.16% | ₩2.30 Billion ≈ $1.56 Million |
₩198.29 Billion ≈ $134.38 Million |
-- |
About Ckd Bio
CKD Bio Corp. engages in the manufacturing and sale of pharmaceutical products in South Korea, Europe, Asia, the Middle East, and internationally. The company is also involved in real estate leasing and related ancillary; bio, cosmetics, and health functional food; property management; advertising communication; consulting, construction, and maintenance of corporate IT systems business. It also e… Read more